Abstract 760P
Background
Although concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer, elderly patients are often intolerable to chemotherapy. It’s urgent to explore a suitable regimen for these population. Cervical squamous cell carcinoma (CSCC) is characterized by the high expression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized anti-EGFR monoclonal antibody with good safety. This study aimed to investigate the efficacy and safety of nimotuzumab plus radiotherapy in the treatment of elderly patients with locally advanced cervical squamous cell carcinoma (LACSCC).
Methods
It’s a prospective, multicenter, and single-arm trial. Key inclusion criteria included aged ≥ 65 years, histologically diagnosed CSCC with clinical stage IB3-ⅣA, ECOG 0-2, and refusing chemotherapy. Patients received nimotuzumab with 200mg/w for 6 weeks, underwent radiotherapy, including intensity-modulated radiotherapy (IMRT), volumetric intensity modulated arc therapy (VMAT) (45-50.4Gy, 1.8-2.0Gy/f, 25-28f), and brachytherapy (HR-CTV D90, 80-85Gy). Brachytherapy combined with external beam radiotherapy was completed within 8 weeks. The current endpoints include objective response rate (ORR), complete response rate (CRR), disease control rate (DCR), and safety.
Results
This trial enrolled 122 elderly LACSCC patients from Nov 2021 to Jan 2023. The median age was 72.5 years old (range from 65 to 92) with clinical stage IB3-ⅣA. The addition of nimotuzumab to radiotherapy exhibited a significant improvement in short-term efficacy with ORR of 87.70% (107/122), CRR of 42.62% (52/122), and DCR of 92.62% (113/122). The partial response was 45.08% (55/122), progressive disease was 2.50% (3/122), and stable disease was 4.92% (6/122). So far, no drug-related adverse events have occurred.
Conclusions
Nimotuzumab plus radiotherapy provided significant improvements in ORR, CRR, and DCR in elderly patients with LACSCC. No drug-related adverse events were observed. Our results demonstrate that nimotuzumab combined with radiotherapy may provide a choice for this population with better efficacy and tolerance.
Clinical trial identification
NCT04976478.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11